How to Secure a Medical Device You Can’t Patch

By Joseph M. Saunders, Founder and CEO, RunSafe Security A medical device cleared today may stay in clinical service for 15 years or more, but the software inside it does not always age well. New vulnerabilities get discovered, open source components fall out of date, and attack techniques keep improving. Frontier AI tools now make…

The post How to Secure a Medical Device You Can’t Patch appeared first on Medical Design and Outsourcing.

Beyond Teleconsultation: Exploring the Role of Mobile Health Technologies in Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a progressive, multisystem disease requiring long-term monitoring of respiratory, cardiac, and functional status. Advances in care have extended survival, increasing the need for continuous, coordinated management. In parallel, digital health technologies have enabled remote monitoring and data collection outside traditional clinical settings. This Viewpoint examines the role of device-based remote monitoring in DMD and argues that it should be understood as an emerging multisystem digital surveillance framework rather than a collection of isolated technologies. This Viewpoint is based on a synthesis of published literature on device-based remote monitoring and digital health technologies in DMD and experiences at our center. The aim was to outline the current clinical and technological landscape and support an interpretive perspective. Device-based monitoring in DMD encompasses a range of technologies, including home spirometry, ventilator-integrated telemonitoring, wearable activity sensors, cardiac rhythm monitoring, and interactive rehabilitation systems. These approaches enable longitudinal assessment of physiological and functional parameters in real-world settings. However, the current evidence base is heterogeneous and largely limited to feasibility studies, small cohorts, and extrapolated data. While data acquisition is technically feasible and increasingly available, integration into clinical workflows remains constrained by the lack of validated digital biomarkers, standardized monitoring frameworks, and interoperable data systems. Remote monitoring in DMD is evolving toward a connected, multisystem model of disease surveillance. Its clinical impact will depend on the validation of digital end points, development of decision support frameworks, and integration into multidisciplinary care pathways. Bridging the gap between data generation and clinical decision-making remains a key priority for future research and implementation. These findings support a shift from isolated technologies toward a coordinated, clinically integrated model of multisystem care in DMD.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/3f71d59c414c9e0a386a2acb7220e948" />

Development and Usability Evaluation of an E-Learning Tool for Blended Learning in Pediatric Endocrinology: Formative Pilot Study

Background: Residents in pediatric endocrinology subspecialty units encounter diverse educational scenarios spanning theory, skills, and attitudes; yet, brief residencies frequently limit their exposure to certain clinical cases. Research in medical education demonstrates that e-learning can address such challenges efficiently. We implemented a blended learning model grounded in the Kolb learning cycle that uses structured, case-based e-learning. Objective: We aimed to evaluate the utility and usability of blended learning using a novel e-learning tool. Methods: We used a problem-solving approach and used the physical separation of case-based e-learning (interactive, patient scenario–based online modules) and theoretical content delivery as the educational model for residents in a pediatric endocrinology and diabetology unit. Residents worked asynchronously (on their own time, not simultaneously with others) on clinical scenarios and completed formative assessments (practice tests designed to provide feedback for learning rather than grades) with immediate feedback using a flipped classroom teaching method, in which students review material before group instruction. In addition, all cases could be discussed with specialists during face-to-face learning opportunities through a blended learning approach that combines online and in-person elements. We evaluated Kirkpatrick level 1 (reaction, how participants respond to training) and level 2 (learning, measured as an increase in knowledge or capability) outcomes using the postgraduate Medical E-learning Evaluation Survey (MEES) and the User Experience Questionnaire (UEQ), which assesses users’ perceptions of e-learning platforms. Results: Questionnaires from 12 pediatric residents and 1 questionnaire from a fourth-year medical student were evaluated. The main strengths identified were the tool’s support for applying content to daily clinical work (12/13, 92% users), provision of timely summaries (n=9, 69% users), access to reliable information sources (n=9, 69% users), and immediate feedback on responses (n=8, 62% users). Key weaknesses included device compatibility for e-learning (n=5, 38% users), limited content personalization (n=4, 31% users), and a lack of a navigation aid (n=4, 31% users). No significant functional issues were reported. The UEQ evaluation showed that dependability received the lowest rating, while attractiveness and stimulation received the highest rating. Conclusions: Our e-learning proposal provides a practical way to apply theoretical knowledge through interactive clinical cases. Evaluations show that users are highly motivated to engage with e-learning, highlighting our tool’s adaptability and effectiveness for postgraduate medical education in pediatric endocrinology. Identifying strengths and weaknesses will guide future improvements. Evaluating various aspects of e-learning remains crucial, as these aspects can affect learning outcomes. However, more longitudinal evaluations of e-learning are necessary to achieve a comprehensive understanding of its effectiveness.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/6e71bb0793753160fbbcd61e16945cfc" />

Latest developments in the use of e-cigarettes by people with schizophrenia spectrum disorders who smoke: a scoping review

BackgroundTobacco use is significantly more prevalent among individuals with schizophrenia spectrum disorders (SSD) compared to the general population, contributing to elevated rates of premature mortality from smoking-related diseases. Despite a decline in smoking prevalence in the general population, individuals with SSD continue to smoke at persistently high rates, driven by biological, psychological, and social factors. Standard smoking cessation approaches yield markedly poorer outcomes in this group compared to non-psychiatric populations. This scoping review aimed to map the emerging evidence on the use of e-cigarettes among individuals with SSD or serious mental illness (SMI).MethodsThis scoping review was conducted in accordance with the Population–Concept–Context (PCC) framework and reported following the PRISMA extension for Scoping Reviews (PRISMA-ScR) guidelines. The review focused on studies published between January 2020 and February 2026, searched on PubMed and EMBASE, providing an up-to-date synthesis of emerging evidence on e-cigarette use in this vulnerable population.ResultsThree studies reported across four publications were included (total N = 323); one research group (Pratt et al.) contributed two separate publications reporting distinct outcomes from the same study cohort. Findings suggest that e-cigarette-based interventions are feasible and acceptable in individuals with SSD and SMI, with preliminary evidence of smoking reduction and decreased exposure to tobacco-related carcinogens. However, sustained harm reduction appeared dependent on a combined approach considering that device provision was empowered in its efficacy to sustain harm reduction over time when integrated with behavioral support.ConclusionsThe available evidence, while preliminary and limited by the small number of included studies, should be interpreted with caution regarding generalizability to patients with Schizophrenia Spectrum Disorders exclusively, as three of the four included publications recruited participants with broader SMI diagnoses of which SSD represents only a subset. Further research, including larger adequately powered trials with standardized outcome measures and longer follow-up, is needed to establish the generalizability and long-term impact of these interventions.

Temporal Interference Transcranial Alternating Current Stimulation for Major Depressive Disorder and Generalized Anxiety Disorder

Conditions: Major Depressive Disorder (MDD); Generalized Anxiety Disorder (GAD)

Interventions: Device: Temporal Interference transcranial Alternating Current Stimulation (TI-tACS); Device: Sham Temporal Interference transcranial Alternating Current Stimulation (TI-tACS)

Sponsors: Central South University; Second Xiangya Hospital of Central South University; Lanzhou University Second Hospital; Neuropsychiatric Institute of Fuzhou Second General Hospital; Affiliated Wuhan Mental Health Center of Huazhong University of Science and Technology; Affiliated WuTaiShan Hospital of Medical College of Yangzhou University; Xianyue Psychiatric Hospital, Xiamen

Not yet recruiting